ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

GLUE vs DNA // ALTMAN Z-SCORE & DEBT/EQUITY

Monte Rosa Therapeutics Inc. (NASDAQ) VS. Ginkgo Bioworks Holdings Inc. (Class A) (NYSE) • 15-METRIC TALLY: GLUE 3 — DNA 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GLUE VS. DNA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC GLUE DNA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -2.97% -21.80% +18.83 GLUE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -0.20% — TIE /net-margins <GO>
Revenue Growth (YoY) — -25.10% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 GLUE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.2 58.4 -12.20 DNA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $927.4M $819.7M $107.7M GLUE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR GLUE REV DNA REV GLUE GROSS % DNA GROSS % GLUE FCF DNA FCF
FY 2025 $0 $170.2M — — -$27.5M -$178.7M
FY 2024 $0 $227.0M — — $38.0M -$382.1M
FY 2023 $0 $251.5M — — -$43.8M -$295.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GLUE // BETA —
DNA // BETA —